---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-004872"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2023-04-18T23:59:59+00:00"
generated_at: "2026-06-17T00:47:05.633214+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ENDRA Life Sciences reports preliminary Q1 2023 net loss of $2.8M; no revenue

## Summary
- Expects no revenue for Q1 2023, consistent with Q1 2022.
- Net loss approximately $2.8M, improving from $2.9M loss in prior year.
- Cash and cash equivalents $2.4M; total assets $6.7M; working capital $4.3M.
- Filed S-1/A for underwritten public offering of common stock and warrants.

## SEC filing metadata
- accession: 0001654954-23-004872
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2023-04-18T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495423004872/0001654954-23-004872-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495423004872/ndra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-004872
- JSON: https://secwatch.observer/filing/0001654954-23-004872.json
- Plain text: https://secwatch.observer/filing/0001654954-23-004872.txt

## Key facts
- Earnings Releases
  ENDRA Life Sciences Inc. reported the quarter ended March 31, 2023 results: revenue no revenue, net income net loss of approximately $2.8 million.
  - Period: the quarter ended March 31, 2023
  - Revenue: no revenue
  - Net income: net loss of approximately $2.8 million
  - Result: preliminary results
  source text: We expect no revenue for the quarter ended March 31, 2023 and did not have revenue for the quarter ended March 31, 2022. We expect to record a net loss of approximately $2.8 million for the quarter ended March 31, 2023, compared to a net loss of approximately $2.9 million for the quarter ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681682/000165495423004872/0001654954-23-004872-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.